 - Multiple myeloma accounts for approximately 1 of all cancers and 10 of hematologic malignancies. Between 50 and 70 of symptomatic patients presented response to induction chemotherapy. The rate of complete responses CR achieved with standard induction of these treatments is less than 5 of cases and the median event-free survival between 2 and 3 years although most of the patients died from the disease. 